Spiolto Respimat

DRUG4 trials

Sponsors

Boehringer Ingelheim, Fundacio Privada Mon Clinic Barcelona

Conditions

Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 4

ANTES B+ Clinical Trial

TerminatedNCT06282861

Fundacio Privada Mon Clinic BarcelonaChronic Obstructive Pulmonary Disease

Start: 2024-02-29End: 2025-01-23Updated: 2025-08-14

Unknown Phase

Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice

CompletedNCT02675517

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2016-01-13End: 2017-04-11Updated: 2018-10-15

Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)

TerminatedNCT02720757

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2016-08-26End: 2017-12-14Updated: 2019-04-16

Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

CompletedNCT05393245

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2022-09-30End: 2022-12-07Updated: 2024-12-04

Related Papers

Swiss Experience in Therapy With Dual Bronchodilation in Chronic Obstructive Pulmonary Disease in Relation to Self-Reported Physical Functionality

Journal of Clinical Medicine Research2021-07-013 citations

Assessment of Patient Experiences with Respimat<sup>®</sup> in Everyday Clinical Practice.

2020-08-285 citations